Aurora, CO, United States of America

Mark W Geraci

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mark W Geraci: Innovator in Cancer Treatment

Introduction

Mark W Geraci is a notable inventor based in Aurora, CO (US). He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Geraci's work focuses on enhancing therapeutic methods for cancer patients.

Latest Patents

Geraci's latest patents include groundbreaking methods that utilize prostacyclin analogs. The first patent provides a method for preventing or reducing the risk of cancer or the progression of premalignant dysplasia in subjects with higher risk factors by administering a therapeutically effective amount of prostacyclin analog. The second patent addresses gefitinib sensitivity-related gene expression, offering a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors. This patent describes methods for selecting cancer patients who may benefit from therapeutic administration of EGFR inhibitors and identifying molecules that enhance responsiveness to these treatments.

Career Highlights

Mark W Geraci is affiliated with the University of Colorado, where he continues to advance research in cancer therapies. His work has the potential to significantly impact patient outcomes and treatment efficacy.

Collaborations

Geraci collaborates with esteemed colleagues, including Robert L Keith and York E Miller, to further his research and innovations in the field.

Conclusion

Mark W Geraci's contributions to cancer treatment through his innovative patents demonstrate his commitment to improving patient care. His work continues to pave the way for advancements in therapeutic methods for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…